PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNe
(Financial Post, 2025-11-03T13:35:00Z)